Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 7/20 | 0.33 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 2/20 | 0.30 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23508063 | 0.84 | GSK3B (0.36) | CACNA1HGSK3BAURKACDK2HRH4 | |
| SCHEMBL23508341 | 0.82 | CDK2 (0.33) | GSK3BCDK2 | |
| SCHEMBL30012211 | 0.82 | CACNA1H (0.34) | CACNA1HGSK3BAURKA | |
| SCHEMBL23508422 | 0.80 | CSNK1E (0.42) | CACNA1HCDK2HRH4 | |
| SCHEMBL23508346 | 0.80 | PTGS2 (0.34) | GSK3BCDK2HRH4 | |
| SCHEMBL23508247 | 0.80 | GSK3B (0.33) | GSK3BCDK2 | |
| SCHEMBL23497496 | 0.79 | CSNK1E (0.46) | — | |
| SCHEMBL29788804 | 0.79 | CSNK1E (0.46) | — | |
| SCHEMBL23497790 | 0.78 | KLK1 (0.36) | GSK3BAURKACDK2 | |
| SCHEMBL23508253 | 0.74 | GSK3B (0.36) | GSK3BCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117034-A1 | PYRAZOLOTRIAZINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-20 | — | — | US | disclosed |
| EP-4073072-A1 | PYRAZOLOTRIAZINES | Bayer Aktiengesellschaft (DE) | 2022-10-19 | — | — | EP | disclosed |
| CN-115023427-A | Pyrazolotriazines | 拜耳公司 | 2022-09-06 | — | — | CN | disclosed |
| WO-2021116178-A1 | PYRAZOLOTRIAZINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117034-A1 | PYRAZOLOTRIAZINES | BRCA1, TPX2, CCND2 | CACNA1H 1874/4885GSK3B 3545/4885ALKBH3 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.